507 related articles for article (PubMed ID: 28711571)
1. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
2. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
5. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Vadhan-Raj S; Fayad LE; Fanale MA; Pro B; Rodriguez A; Hagemeister FB; Bueso-Ramos CE; Zhou X; McLaughlin PW; Fowler N; Shah J; Orlowski RZ; Samaniego F; Wang M; Cortes JE; Younes A; Kwak LW; Sarlis NJ; Romaguera JE
Ann Oncol; 2012 Jun; 23(6):1640-5. PubMed ID: 22015451
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
[TBL] [Abstract][Full Text] [Related]
8. Rasburicase for the management of tumor lysis syndrome in neonates.
McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS
Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218
[TBL] [Abstract][Full Text] [Related]
9. Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Personett HA; Barreto EF; McCullough KB; Dierkhising R; Leung N; Habermann TM
Leuk Lymphoma; 2019 Sep; 60(9):2271-2277. PubMed ID: 31223041
[TBL] [Abstract][Full Text] [Related]
10. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Galardy PJ; Hochberg J; Perkins SL; Harrison L; Goldman S; Cairo MS
Br J Haematol; 2013 Nov; 163(3):365-72. PubMed ID: 24032600
[TBL] [Abstract][Full Text] [Related]
11. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
[TBL] [Abstract][Full Text] [Related]
12. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
13. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
Bessmertny O; Robitaille LM; Cairo MS
Curr Pharm Des; 2005; 11(32):4177-85. PubMed ID: 16375739
[TBL] [Abstract][Full Text] [Related]
14. [Effect of the Administration Period of Rasburicase in Japanese Adult Hematological Malignancy Patients at High-Risk for Tumor Lysis Syndrome].
Kobayashi S; Yasu T; Sato K; Ohno N; Kuroda S
Gan To Kagaku Ryoho; 2018 May; 45(5):879-881. PubMed ID: 30026457
[TBL] [Abstract][Full Text] [Related]
15. Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
Chiang J; Chan A; Lian T; Tay K; Quek R; Tao M; Lim ST
Asia Pac J Clin Oncol; 2011 Dec; 7(4):351-6. PubMed ID: 22151984
[TBL] [Abstract][Full Text] [Related]
16. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Ribeiro RC; Pui CH
Clin Lymphoma; 2003 Mar; 3(4):225-32. PubMed ID: 12672271
[TBL] [Abstract][Full Text] [Related]
17. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Wössmann W; Schrappe M; Meyer U; Zimmermann M; Reiter A
Ann Hematol; 2003 Mar; 82(3):160-5. PubMed ID: 12634948
[TBL] [Abstract][Full Text] [Related]
18. Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.
Gopakumar KG; Thankamony P; Seetharam S; P K
Pediatr Hematol Oncol; 2017 May; 34(4):206-211. PubMed ID: 28872997
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Vines AN; Shanholtz CB; Thompson JL
Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
